TruSpine Technologies Plc

Transaction in Own Shares • Apr 25, 2025

National Storage Mechanism | Additional information

RNS Number : 2571G

TruSpine Technologies PLC

25 April 2025

25 April 2025

TruSpine Technologies plc

("TruSpine" or the "Company")

Issue of Equity

TruSpine Technologies Plc, the medical device company focused on the spinal (vertebral) stabilisation market, announces that on 28 March 2025, the Company issued 7,103,623 new ordinary shares ("Creditor Shares") of 0.01 pence each at a price of 1.5 pence per Creditor Share to settle creditor liabilities of approximately £106,554. Due to an administrative oversight by the Company, no announcement or application was made for these shares to be admitted to trading on the AQSE Market.

Admission

Application has now been made for the Creditor Shares to be admitted to trading on the Aquis Stock Exchange AQSE Growth Market on or around 1 May 2025 ("Admission") and will rank pari passu with the ordinary shares of the Company in issue.

Total Voting Rights

Following Admission, the Company's issued share capital will comprise 160,131,523 ordinary shares of 0.01p each, with each share carrying the right to one vote, therefore the total number of voting rights in the Company will be 160,131,523. This figure may be used by shareholders as the denominator for calculations by which they will determine if they are required to notify their interest in the Company, or a change to their interest in the Company, under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

This announcement contains inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

-END-

TruSpine Investor Hub	https://investorhub.truspinetech.com
TruSpine Technologies Plc	Tel: +44 (0)20 7118 0852
Geoff Miller, Non-executive Chairman
Cairn Financial Advisers LLP (AQSE Corporate Adviser)	Tel: +44 (0)20 7213 0880
Liam Murray / Ludovico Lazzaretti
Peterhouse Capital Limited (Broker & Financial Adviser)	Tel: +44 (0)20 7469 0930
Lucy Williams / Duncan Vasey
Novus Communications (PR and IR)	Tel: +44 (0)1273 704 473
Alan Green / Jacqueline Briscoe	[email protected]

Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as ''believe'', ''could'', "should" ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect", ''will'' or the negative of those, variations or comparable expressions, including references to assumptions. These forward-looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NEXFLFFISAIEFIE